COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022 [0.03%]
2021年7月至2022年1月德尔塔和奥密克戎变异株流行期间按种族/民族和疫苗接种状态划分的成人新冠肺炎住院患者特征——来自 COVID-NET 的14州数据
Christopher A Taylor,Michael Whitaker,Onika Anglin et al.
Christopher A Taylor et al.
Beginning the week of December 19-25, 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant in the United States (i.e., accounted for >50% of sequenced isolates).* In...
Health Needs and Use of Services Among Children with Developmental Disabilities - United States, 2014-2018 [0.03%]
美国2014-2018年残疾儿童健康需求和利用服务情况
Mary E Cogswell,Eric Coil,Lin H Tian et al.
Mary E Cogswell et al.
Developmental delays, disorders, or disabilities (DDs) manifest in infancy and childhood and can limit a person's function throughout life* (1-3). To guide strategies to optimize health for U.S. children with DDs, CDC analyzed data from 44,...
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022 [0.03%]
美国2021年3月—2022年1月在预防新冠感染导致的有创通气和死亡方面mRNA疫苗有效性下降程度——2021年3月-2022年1月
Mark W Tenforde,Wesley H Self,Manjusha Gaglani et al.
Mark W Tenforde et al.
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well mRNA vaccines protect against the most severe outcomes of these hospitaliza...
Thomas D Filardo,Pei-Jean Feng,Robert H Pratt et al.
Thomas D Filardo et al.
During 1993-2019, the incidence of tuberculosis (TB) in the United States decreased steadily; however, during the later years of that period the annual rate of decline slowed (1) until 2020 when a substantial decline (19.9%) was observed. T...
Hospitalization of Infants and Children Aged 0-4 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022 [0.03%]
2020年3月至2022年2月14个地区实验室确认的儿童和婴幼儿新型冠状病毒感染住院病例——COVID-NET
Kristin J Marks,Michael Whitaker,Nickolas T Agathis et al.
Kristin J Marks et al.
The B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, has been the predominant circulating variant in the United States since late December 2021.* Coinciding with increased Omicron circulation, COVID-19-associated h...
Progress Toward Achieving and Sustaining Maternal and Neonatal Tetanus Elimination - Worldwide, 2000-2020 [0.03%]
2000-2020年全球产科和新生儿破伤风消除进展及可持续性状况报告
Florence A Kanu,Nasir Yusuf,Modibo Kassogue et al.
Florence A Kanu et al.
Maternal and neonatal tetanus (MNT)* remains a major cause of neonatal mortality with an 80%-100% case-fatality rate among insufficiently vaccinated mothers after unhygienic deliveries, especially in low-income countries (1). In 1989, the W...
Monica E Cornelius,Caitlin G Loretan,Teresa W Wang et al.
Monica E Cornelius et al.
Although cigarette smoking has declined over the past several decades, a diverse landscape of combustible and noncombustible tobacco products has emerged in the United States (1-4). To assess recent national estimates of commercial tobacco ...
The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022 [0.03%]
美国疾病控制与预防中心关于莫德纳新型冠状病毒肺炎疫苗在≥18岁成人中使用的咨询委员会免疫实践建议及关于mRNA新冠疫苗基础接种间隔的考虑事项简报——美国，2022年2月
Megan Wallace,Danielle Moulia,Amy E Blain et al.
Megan Wallace et al.
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the va...
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022 [0.03%]
5至11岁和12至15岁儿童接种2剂BNT162b2（辉瑞/BioNTech）mRNA疫苗预防SARS-CoV-2感染的有效性——“PROTECT”队列研究，2021年7月—2022年2月
Ashley L Fowlkes,Sarang K Yoon,Karen Lutrick et al.
Ashley L Fowlkes et al.
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) on May 12, 2021, and for children aged 5-11 ...